Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.

Medicine - 25 Jun 2021

Dong Yong, Li Qijun, Miao Qian, Li Da

Abstract excerpt

RATIONALE: The guidelines recommended gefitinib as a first-line targeted treatment for stage IV non-small-cell lung cancer (NSCLC) patients with EGFR mutations. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment for patients without T790m mutation. The case is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Chemoradiotherapy
Share to Drug Substitution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Neoplasm Recurrence, Local

Share to Progression-Free Survival

Share to Salvage Therapy

Source

Open in PubMed Open full text

Identifiers

PMID: 34160440
DOI: 10.1097/MD.0000000000026450
PMCID: PMC8238270

Provenance

PubMed metadata and Literature Corpus relationships.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.PMID 34160440Read ↗

Trametinib Monotherapy for the Treatment of Brain Metastasis From Non-small-cell Lung Cancer: a Case ReportSemantic proximity Read ↗

Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.Semantic proximity Read ↗

Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.Semantic proximity Read ↗

Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report.Semantic proximity Read ↗

First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.Semantic proximity Read ↗

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.Semantic proximity Read ↗

[Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review].Semantic proximity Read ↗

Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.Semantic proximity Read ↗

Trametinib Monotherapy for the Treatment of Brain Metastasis from NSCLC: A Case Report and Literature ReviewSemantic proximity Read ↗

The Efficacy of EGFR-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Synchronous Brain Metastasis: A Real-World StudySemantic proximity Read ↗

Complete response in a lung adenocarcinoma with pleural metastases initially treated with gefitinib and switched to osimertinib after cerebral oligo-progression with unknown T790M mutation: a case report and review of literature.Semantic proximity Read ↗

Significant benefit of high-dose furmonertinib in the treatment of leptomeningeal metastases from non-small-cell lung cancer with EGFR ex19Del mutation: Two case reports and a literature reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.